Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626832 · ClinicalTrials.gov registry record · NA
Regulation of Arginine-vasopressin (AVP)
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT02626832 is a NA study that has completed, run by Yale University. The registered enrollment target is 25 participants.
The verdict
NCT02626832, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study aims to develop a method for the assessment of central NMDA receptor functioning in patients with depression and schizophrenia. For this purpose a transitional approach is used based on preclinical studies that show a dose-dependent relationship between the activity of hypothalamic NMDA receptor and plasma AVP response to increasing plasma osmolality. Patients with schizophrenia, depression and healthy controls participated in this study. The Investigators found that in a subgroup of patients with schizophrenia the AVP response was low and that in a subgroup of subjects with depression the AVP response was high compared to healthy controls.
Interventions
- OTHER Procedural
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-02 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02626832
The ClinicalTrials.gov registry entry for NCT02626832 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Procedural is the first listed.
NCT02626832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02626832 about?
NCT02626832 is a clinical study titled "Regulation of Arginine-vasopressin (AVP)". This study aims to develop a method for the assessment of central NMDA receptor functioning in patients with depression and schizophrenia. For this purpose a transitional approach is used based on preclinical studies that show a dose-dependent relationship between the activity of hypothalamic NMDA r...
What is the current status of trial NCT02626832?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2010-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02626832?
The interventions under investigation include: Procedural (OTHER).
Who is sponsoring clinical trial NCT02626832?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.